Last reviewed · How we verify
NCT03262922: PRESSY
Clinical and Paraclinical Characteristics of the Systemic Scleroderma Cohort According to the Criteria ACR 2013 and the History of Professional Exposure or of Agricultural Environment
trial in Systemic Scleroderma in 327 participants. Completed in 18 February 2022.
31 December 2019
Quick facts
| Lead sponsor | Rennes University Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 327 |
| Start date | 29 July 2016 |
| Primary completion | 31 December 2019 |
| Estimated completion | 18 February 2022 |
| Sites | 1 location across France |
Conditions studied
- Systemic Scleroderma — all drugs for Systemic Scleroderma →
Sponsor
Rennes University Hospital
Who can join
18 and older, any sex, with Systemic Scleroderma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study is to compare the exposure to environmental and professional toxics by patients with systemic scleroderma and by patients not achieved by this pathology.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03262922
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Systemic Scleroderma
Currently open trials in the same condition.
- NCT06056921 — Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease · Phase 1 · recruiting
- NCT05726630 — Clinical Study of Divozilimab in Patients With Systemic Scleroderma · Phase 3 · active not recruiting
- NCT04380831 — TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis · EARLY_PHASE1 · recruiting
- NCT03816345 — Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NI · Phase 1 · recruiting
Other Rennes University Hospital trials
Trials by the same sponsor.
- NCT07527949 — PASTRAMI : Patient-specific Statistics for Microstructure-augmented Connectomics · NA · not yet recruiting
- NCT07449832 — Sperm Epigenome in Hodgkin Lymphoma · NA · not yet recruiting
- NCT06950398 — Normothermic Oxygenated Perfusion (NMP) Viability Testing Before Transplantation of Discarded Livers · Phase 2 · not yet recruiting
- NCT07188753 — Randomized Controlled Trial Testing the Efficacy of Transcranial Magnetic Stimulation by Accelerated & High-dose Theta-b · NA · not yet recruiting
- NCT06898099 — Evaluation of the Efficacy of E2R Hypnotherapy in the Management of Chronic Insomnia in Primary Care (HypERR) · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03262922 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rennes University Hospital
- Last refreshed: 4 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03262922.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing